Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Buntanetap (ANVS401) in Alzheimer's disease. The expected timing is based on the latest available company guidance and may change.
05/15/26:- AD Ph3 NCT06709014 is 85% enrolled. Enrollment Summer 2026. Readouts and NDA plans Early 2027/2028. 07/07/26:- AD Ph3 NCT06709014 fully enrolled. Symptomatic topline Q1 2027; disease-modifying topline Q1 2028. 08/14/26:- AD Ph3 is fully enrolled with 850 patients. AD OLE will initiate in October 2026. Symptomatic topline data will be reported in Q1 2027; disease-modifying data will follow in Q1 2028.
Verification
Confirm timing and program details against the company announcement or filing.